Covaxin Gets WHO Approval

Reports are emerging that the technical committee of the World Health Organization (WHO) has granted Emergency Use Listing (EUL) to India’s indigenously developed COVID-19 vaccine, Covaxin. This is a major leap in the Hyderabad-based company’s efforts to market the vaccine across the globe.

Covaxin is now added to a growing portfolio of vaccines validated by WHO for the prevention of COVID-19. The approval has been delayed for a long time after WHO has returned the application with any queries. The company managed to clear all those queries and got the nod.

Covaxin has demonstrated 77.8 percent efficacy in its Phase 3 clinical trial. Covaxin is the second widely administered vaccine in India. So far, thirteen countries have emergency approval for the vaccine. With WHO approval, the support base will only increase.

Most of the existing COVID-19 vaccines use the new technology of mRNA but Covaxin is developed using the inactivated virus.